Various service providers claim to possess the required equipment for API synthesis under hazardous (high / low temperature and high / low pressure) conditions. Over time, the shift to high energy synthesis chemistries has demonstrated the benefits of closed, continuous reaction processes. Although many players continue to prefer the standard batch process, many are gradually adopting continuous flow technologies, especially for hazardous reactions.
To order this 240+ page report, which features 90+ figures and 100+ tables, please visit this link
The USD 29 Billion (by 2030) financial opportunity within the HEC / hazardous services market has been analyzed across the following segments:
- Reaction Conditions
- High Temperature
- Low Temperature
- High Pressure
- Low Pressure
- Key Geographical Regions
- North America
- Europe
- Asia-Pacific and Rest of the World
The High Energy Chemistry / Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature / Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030 report features the following companies, which we identified to be key players in this domain:
- AGC Chemicals
- Beijing Mediking Biopharm
- Cambrex
- CordenPharma
- Evonik Indiustries
- Hovione
- Patheon
- PCI Synthesis
- Siegfried
Table of Contents
- Preface
2. Executive Summary
Introduction
- Case Study: Comparison of Small Molecules and Large Molecules
- Current Market Landscape
- Regional Capability Assessment
- Company Competitiveness Analysis
- Company Profiles
- Case Study I: Synthesis Reaction Portfolio of Companies
- Case Study II: Innovation Mapping in HEC Market
- Market Forecast
- SWOT Analysis
- Executive Insights
- Impact of Covid-19 Pandemic on the HEC-based API Manufacturing Services Market
- Concluding Remarks
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/high-energy-chemistry.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
According to industry experts, handheld ultrasound imaging devices are being adopted at a faster pace by different end-users owing to their higher efficiency and wider applicability.
Further, these devices have proven to be useful in quarantining patients demonstrating symptoms of pleural wall thickening and lung congestion, a characteristic of pneumonia, as well as observed in patients suffering from the novel coronavirus (COVID-19).
To order this 235+ page report, which features 95+ figures and 110+ tables, please visit this link The USD 1.1 billion (by 2030) financial opportunity within the handheld ultrasound imaging devices market has been analyzed across the following segments:Application AreaCardiac ScanningEmergency MedicinesGynecological / Obstetrics ScanningMusculoskeletal ScanningPulmonary ScanningUrological ScanningVascular SurgeryOther Application Areas Type of Transducer ArrayCurvedEndocavityLinearPhasedOther Scanners Type of SoftwareSmartphone ApplicationsCustomized Software End-UsersAmbulatory Surgical CentersDiagnostic Imaging CentersHospitalsMaternity ClinicsSpecialty ClinicsOther End-Users Key Geographical Regions North AmericaEuropeAsia-Pacific and the Rest of the World The Global Handheld Ultrasound Imaging Devices Market, 2020-2030, report features the following companies, which we identified to be key players in this domain: Aidmax MedicalBeijing Konted Medical TechnologyBiim UltrasoundBreastITButterfly NetworkCJ MedicalClarius Mobile HealthEchoNousFujifilmGE HealthcareGuangzhou Top Medical EquipmentHealcerionInterson Medical InstrumentsPhilipsSomax SystemsVINNOWuHan Youkey Bio-Medical ElectronicsYor Labs Table of Contents Preface 2.
Executive Summary Introduction Market Landscape Company Profiles Brand Positioning Analysis of Key Players Partnerships and Collaborations Cost Saving Analysis Demand Analysis Market Forecast End-User Specific Opportunity Analysis Case Study: Impact of Coronavirus Outbreak Conclusion Executive Insights Appendix 1: Tabulated Data Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]
Huntington's Disease Treatment Market Research Report: by drug type (tetrabenazinedeutetrabenazine, chlorpromazine and others), Treatment (symptomatic therapy, disease-modifying therapy), End-users (hospital and others) - Forecast Till 2027Market Highlights:Huntington Disease is a brain disorder that causes uncontrolled movements, emotional problems, and loss of thinking ability.
Early symptoms can include irritability, depression, small involuntary movements, poor coordination, and trouble learning new information or making decisions.
The individuals suffering from this disorder may have trouble in walking, speaking, and swallowing.
People with this disorder also experience decline in thinking and reasoning abilities.
Individuals suffering with this huntington disease usually live about 15 to 20 years after signs and symptoms begin.Huntington’s disease treatment market is expected to grow in the near future due to rise in incidence of genetic diseases, increasing research and development activities to develop drugs that can be used for treatment of this disorder and developing healthcare sector.
Key players in market are making their position in many developing countries due to the FDI policies regulated within the pharmaceuticals industry in such countries with increasing consumer demands towards maintaining aesthetic appearance is also driving the market for global huntington’s disease treatment market.However, some factors that can hamper the growth of this market are rising side effect associated with drugs, lack of awareness regarding genetic disorder and alternative treatment plan.
